

WHAT IS CLAIMED IS:

1. A method of modulating the trafficking or activation of a leukocyte in an animal, said method comprising contacting myeloid lineage cells in said animal with a therapeutic amount of:
 - a) an agonist of a mammalian OX2 protein; or
 - b) an antagonist of a mammalian OX2 protein.
2. The method of Claim 1, wherein said:
 - a) mammalian OX2 protein is a primate protein;
 - b) antagonist is an antibody which binds to said mammalian OX2; or
 - c) said cells are monocyte/macrophage lineage cells.
3. The method of Claim 2, wherein said myeloid lineage cells include a monocyte, macrophage, microglial, or dendritic cell.
4. The method of Claim 1, wherein said animal exhibits signs or symptoms of an inflammatory, infective, leukoproliferative, neurodegenerative, or post-traumatic condition.
5. The method of Claim 4, wherein said sign or symptom is in neural tissue; lymphoid tissue; myeloid tissue; pancreas; gastrointestinal tissue; thyroid tissue; muscle tissue; or skin or collagenous tissue.
6. The method of Claim 1, wherein said modulating is inhibiting function of said leukocyte cell.
7. The method of Claim 6, wherein said administering is said agonist.

8. The method of Claim 7, wherein said agonist is said mammalian OX2.

9. The method of Claim 7, wherein said animal is experiencing signs or symptoms of autoimmunity; an inflammatory condition; an infection; tissue specific autoimmunity; degenerative autoimmunity; rheumatoid arthritis; atherosclerosis; multiple sclerosis; vasculitides; delayed hypersensitivities; skin grafting; a transplant; spinal injury; stroke; neurodegeneration; or ischemia.

10. The method of Claim 7, wherein said administering is in combination with:

- a) an anti-inflammatory cytokine agonist or antagonist;
- b) an analgesic;
- c) an anti-inflammatory agent; or
- d) a steroid.

11. The method of Claim 1, wherein said modulating is enhancing function of said leukocyte cell.

12. The method of Claim 11, wherein said administering is said antagonist.

13. The method of Claim 12, wherein said antagonist is:

- a) an antibody which binds to said mammalian OX2; or
- b) a mutein of said mammalian OX2 which competes with said mammalian OX2 in binding to an OX2 receptor, but does not substantially signal.

14. The method of Claim 12, wherein said animal experiences signs or symptoms of wound healing or clot formation.

15. The method of Claim 12, wherein said administering is in combination with:

- a) an angiogenic factor;
- 5 b) a growth factor, including FGF or PDGF;
- c) an antibiotic; or
- d) a clotting factor.

10 16. A method of modulating the activation of a leukocyte in a tissue, said method comprising contacting myeloid lineage cells in said tissue with:

- a) an agonist of a mammalian OX2 protein; or
- b) an antagonist of a mammalian OX2 protein.

15 17. The method of Claim 16, wherein said modulating is inhibiting said leukocyte cell, and said contacting is with said agonist.

20 18. The method of Claim 17, wherein said administering is in combination with:

- a) an anti-inflammatory cytokine agonist or antagonist;
- b) an analgesic;
- c) an anti-inflammatory agent; or
- 25 d) a steroid.

19. The method of Claim 16, wherein said modulating is enhancing, and said contacting is with said antagonist.

30 20. The method of Claim 19, wherein said administering is in combination with:

- a) an angiogenic factor;
- b) a growth factor, including FGF or PDGF;
- c) an antibiotic; or
- 35 d) a clotting factor.

SEQUENCE SUBMISSION

SEQ ID NO: 1 is primate, e.g., human, OX2 sequence.

SEQ ID NO: 2 is rodent, e.g., mouse, OX2 sequence.

5 SEQ ID NO: 3 is rodent, e.g., rat, OX2 sequence.

<110> Schering Corporation

10 <120> Novel Uses of Mammalian OX2 Protein and Related Reagents

<130> DX0936K

<140>

<141>

15 <160> 3

<170> PatentIn Ver. 2.0

<210> 1

<211> 274

<212> PRT

20 <213> primate.

<400> 1

Val Ile Arg Met Pro Phe Ser His Leu Ser Thr Tyr Ser Leu Val Trp
1 5 10 15

25 Val Met Ala Ala Val Val Leu Cys Thr Ala Gln Val Gln Val Val Thr

Gln Asp Glu Arg Glu Gln Leu Tyr Thr Thr Ala Ser Leu Lys Cys Ser
35 40 45

Leu Gln Asn Ala Gln Glu Ala Leu Ile Val Thr Trp Gln Lys Lys Lys

Ala Val Ser Pro Glu Asn Met Val Thr Phe Ser Glu Asn His Gly Val
65 70 75 80

Val Ile Gln Pro Ala Tyr Lys Asp Lys Ile Asn Ile Thr Gln Leu Gly

Leu Gln Asn Ser Thr Ile Thr Phe Trp Asn Ile Thr Leu Glu Asp Glu

Gly Cys Tyr Met Cys Leu Phe Asn Thr Phe Gly Phe Gly Lys Ile Ser

Gly Thr Ala Cys Leu Thr Val Tyr Val Gln Pro Ile Val Ser Leu His

Tyr Lys Phe Ser Glu Asp His Leu Asn Ile Thr Cys Ser Ala Thr Ala

143	150	155	160
Arg Pro Ala Pro Met	Val Phe Trp Lys	Val Pro Arg Ser Gly	Ile Glu
	165	170	175

Asn Ser Thr Val Thr Leu Ser His Pro Asn Gly Thr Thr Ser Val Thr

Ser Ile Leu His Ile Lys Asp Pro Lys Asn Gln Val Gly Lys Glu Val

50 Ile Cys Gln Val Leu His Leu Gly Thr Val Thr Asp Phe Lys Gln Thr

210	215	220
Val Asn Lys Gly Tyr Trp	Phe Ser Val Pro Leu	Leu Leu Ser Ile Val
225	230	235

225 230 235 240
Ser Leu Val Ile Leu Leu Val Leu Ile Ser Ile Leu Leu Tyr Trp Lys

55 Arg His Arg Asn Gln Asp Arg Gly Glu Leu Ser Gln Gly Val Gln Lys

	260	265	270
Met Thr			

<210> 2
 <211> 278
 <212> PRT
 <213> rodent

5

<400> 2

Met	Ala	Ser	Leu	Val	Phe	Arg	Arg	Pro	Phe	Cys	His	Leu	Ser	Thr	Tyr
1				5					10					15	
Ser	Leu	Ile	Trp	Gly	Met	Ala	Ala	Val	Ala	Leu	Ser	Thr	Ala	Gln	Val
			20					25					30		
Glu	Val	Val	Thr	Gln	Asp	Glu	Arg	Lys	Ala	Leu	His	Thr	Thr	Ala	Ser
		35					40					45			
Leu	Arg	Cys	Ser	Leu	Lys	Thr	Ser	Gln	Glu	Pro	Leu	Ile	Val	Thr	Trp
	50					55					60				
Gln	Lys	Lys	Lys	Ala	Val	Ser	Pro	Glu	Asn	Met	Val	Thr	Tyr	Ser	Lys
	65			70					75					80	
Thr	His	Gly	Val	Val	Ile	Gln	Pro	Ala	Tyr	Lys	Asp	Arg	Ile	Asn	Val
			85					90					95		
Thr	Glu	Leu	Gly	Leu	Trp	Asn	Ser	Ser	Ile	Thr	Phe	Trp	Asn	Thr	Thr
			100					105					110		
Leu	Glu	Asp	Glu	Gly	Cys	Tyr	Met	Cys	Leu	Phe	Asn	Thr	Phe	Gly	Ser
		115					120					125			
Gln	Lys	Val	Ser	Gly	Thr	Ala	Cys	Leu	Thr	Leu	Tyr	Val	Gln	Pro	Ile
		130				135					140				
Val	His	Leu	His	Tyr	Asn	Tyr	Phe	Glu	Asp	His	Leu	Asn	Ile	Thr	Cys
	145				150				155					160	
Ser	Ala	Thr	Ala	Arg	Pro	Ala	Pro	Ala	Ile	Ser	Trp	Lys	Gly	Thr	Gly
				165				170					175		
Thr	Gly	Ile	Glu	Asn	Ser	Thr	Glu	Ser	His	Phe	His	Ser	Asn	Gly	Thr
			180					185					190		
Thr	Ser	Val	Thr	Ser	Ile	Leu	Arg	Val	Lys	Asp	Pro	Lys	Thr	Gln	Val
		195					200					205			
Gly	Lys	Glu	Val	Ile	Cys	Gln	Val	Leu	Tyr	Leu	Gly	Asn	Val	Ile	Asp
		210				215					220				
Tyr	Lys	Gln	Ser	Leu	Asp	Lys	Gly	Phe	Trp	Phe	Ser	Val	Pro	Leu	Leu
					230					235				240	
Leu	Ser	Ile	Val	Ser	Leu	Val	Ile	Leu	Leu	Val	Leu	Ile	Ser	Ile	Leu
				245					250				255		
Leu	Tyr	Trp	Lys	Arg	His	Arg	Asn	Gln	Glu	Arg	Gly	Glu	Ser	Ser	Gln
			260				265						270		
Gly	Met	Gln	Arg	Met	Lys										
				275											

<210> 3
 <211> 278
 <212> PRT
 <213> rodent

45

<400> 3

Met	Gly	Ser	Pro	Val	Phe	Arg	Arg	Pro	Phe	Cys	His	Leu	Ser	Thr	Tyr
1				5					10					15	
Ser	Leu	Leu	Trp	Ala	Ile	Ala	Ala	Val	Ala	Leu	Ser	Thr	Ala	Gln	Val
			20					25					30		
Glu	Val	Val	Thr	Gln	Asp	Glu	Arg	Lys	Leu	Leu	His	Thr	Thr	Ala	Ser
		35					40					45			
Leu	Arg	Cys	Ser	Leu	Lys	Thr	Thr	Gln	Glu	Pro	Leu	Ile	Val	Thr	Trp
	50					55					60				
Gln	Lys	Lys	Lys	Ala	Val	Gly	Pro	Glu	Asn	Met	Val	Thr	Tyr	Ser	Lys
	65				70					75					80

